Tools

LEADER 02985nam a2200589 i 4500

001 on1500632213;

005 20250422153029.0;

006 m o d f ;

007 cr |||||||||||;

008 250221s2024 dcu o f000 0 eng c;

035 a| (Sirsi) o1500632213;

035 a| (OCoLC)1500632213;

042 a| pcc;

043 a| n-us---;

049 a| XZL4;

074 a| 0512-A-01 (online);

086 0 a| HE 22.2:IN 8/4;

245 00 a| Medicare intravenous immune globulin (IVIG) demonstration evaluation, final report to Congress /.;

264 1 a| Washington, D.C. :b| Health and Human Services Department, Centers for Medicare and Medicaid Services,c| 2024.;

300 a| 1 online resource (27 pages);

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

500 a| In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).;

500 a| United States federal government branch: Executive branch.;

500 a| Access ID (GovInfo): CMR-HE22-00191112.;

500 a| Legal authority: Section 101 of the Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012 (Medicare IVIG Access Act), Public Law 112-242; Section 104, Division CC, of the Consolidated Appropriations Act, 2021 (Pub. L.116-260).;

500 a| United States Congress receiving chamber(s): United States House of Representatives and Senate.;

500 a| United States Congress receiving committee(s): Committee on Energy and Commerce, Committee on Ways and Means.;

500 a| Submitted during Congress: 118th.;

500 a| Date issued: October 17, 2024.;

588 a| Description based on online resource; title from PDF title screen (GovInfo, viewed February 20, 2025).;

650 0 a| Intravenous therapyz| United States.=| ^A310623;

650 0 a| Medicare.=| ^A6515;

650 0 a| Medical care, Cost ofz| United States.=| ^A4211;

650 0 a| Health insurancez| United States.=| ^A623;

650 7 a| Medicare.2| lst;

650 7 a| Health care costs and insurance.2| lst;

710 2 a| Centers for Medicare & Medicaid Services (U.S.),e| issuing body.=| ^A503728;

856 40 u| https://purl.fdlp.gov/GPO/gpo2375817| 0;

856 4 z| Address at time of PURL creationu| https://www.govinfo.gov/app/details/CMR-HE22-00191112;

949 a| Click on web addressw| asish| joyner94;

994 a| C0b| GPO;

922 a| BIBCONEWb| 20250221;

922 a| CMRb| 20250221;

596 a| 1;

998 a| 6563498;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6563498-1001l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 3/19/2025x| EDOCUMENTz| JERESOURCE;

Medicare intravenous immune globulin (IVIG) demonstration evaluation, final report to Congress /.

Other author	Centers for Medicare & Medicaid Services (U.S.), issuing body.
Other author	United States. Congress. House. Committee on Energy and Commerce.
Other author	United States. Congress. House. Committee on Ways and Means.
Format	Electronic
Publication	Washington, D.C. : Health and Human Services Department, Centers for Medicare and Medicaid Services, 2024.
Description	1 online resource (27 pages)
Supplemental Content	https://purl.fdlp.gov/GPO/gpo237581
Supplemental Content	Address at time of PURL creation
Subjects	Immunoglobulins--Therapeutic use. --Government policy. --United States. Intravenous therapy--United States. Medicare. Medical care, Cost of--United States. Health insurance--United States.

General note	In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).
General note	United States federal government branch: Executive branch.
General note	Access ID (GovInfo): CMR-HE22-00191112.
General note	Legal authority: Section 101 of the Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012 (Medicare IVIG Access Act), Public Law 112-242; Section 104, Division CC, of the Consolidated Appropriations Act, 2021 (Pub. L.116-260).
General note	United States Congress receiving chamber(s): United States House of Representatives and Senate.
General note	United States Congress receiving committee(s): Committee on Energy and Commerce, Committee on Ways and Means.
General note	Submitted during Congress: 118th.
General note	Date issued: October 17, 2024.
Source of description	Description based on online resource; title from PDF title screen (GovInfo, viewed February 20, 2025).
GPO item number	0512-A-01 (online)
Govt. docs number	HE 22.2:IN 8/4

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Online Content https://purl.fdlp.gov/GPO/gpo237581 Address at time of PURL creation	✔ Available

Medicare intravenous immune globulin (IVIG) demonstration evaluation, final report to Congress /.

Click here for more information about this title

Availability